Frontlight ResearchEarly access
Active, not recruitingPhase 3
Study of OT-101 in Treating Myopia
Key facts
- Who runs it
- Ocumension (Hong Kong) Limited
- Where
- Cleveland, Colorado Springs, Cranberry Township, Erie, Fort Collins, Gainesville, Indianapolis, Jacksonville, Memphis, Mint Hill, Pittsburgh, Rockville, San Antonio, Shelby, and Washington, United StatesSee the 15 sitesAlso in 5 other countries, 16 sites
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 678 people, planned
- Started
- 1 Apr 2021
- Expected to end
- Apr 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- OT-101 Ophthalmic Solution
- Vehicle
- Record updated
- 8 August 2023
Who can take part
- Age
- 3 years to 15 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Have refractive error by cycloplegic autorefraction at baseline (Visit 1) in the study eye of:; myopia greater or equal to -1.00D of spherical equivalent; astigmatism less than or equal to 1.50DC; progression of at least -0.50D of spherical equivalent in the last 12 months
Who cannot take part
- Have undergone any myopia control treatment including orthokeratology, rigid gas-permeable contact lenses, bifocal contact lenses, progressive addition spectacle lenses, or other lenses to reduce myopia progression in the previous 6 months. Myopic correction in the form of single-vision eyeglasses and/or single-vision soft contact lenses are allowed
- Have undergone any form of refractive eye surgery including incisional keratotomy, photorefractive keratectomy [PRK], laser in situ keratomileusis [LASIK], laser-assisted sub- epithelial keratectomy [LASEK]), corneal inlay procedures, conductive keratoplasty, small incision lenticule extraction (SMILE), cataract extraction, or any form of intraocular lens implantation
- Have active or a history of chronic or recurrent episodes of ocular inflammation (e.g. moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis) in either eye
Where in United States
Also in 5 other countries, 16 sites
- University Hospitals Cleveland Medical Center*Cleveland, United States
- Colorado Vision InstituteColorado Springs, United States
- Scott & Christie and AssociatesCranberry Township, United States
- Pediatric Ophthalmology of Erie, IncErie, United States
- Eye Center of Northern Colorado, PCFort Collins, United States
- Family FocusGainesville, United States
- Indiana University Health Physicians Pediatric OphthalmologyIndianapolis, United States
- Pediatric Eye Consultants of North FloridaJacksonville, United States
- Total Eye Care, P.A.Memphis, United States
- Pure Ophthalmic ResearchMint Hill, United States
- UPMC Children's HospitalPittsburgh, United States
- Kids Eye Care of MarylandRockville, United States
- San Antonio Eye CenterSan Antonio, United States
- CORE, Inc.Shelby, United States
- Comprehensive Eye Care, Ltd.Washington, United States
About the trial
What the trial wants to find out
This is a phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter safety, tolerability, and efficacy study of atropine sulfate 0.01% (OT-101) as an investigational treatment for myopia in pediatric subjects
The 3 groups in the trial
- OT-101 aloneTreatment being tested
Atropine Sulfate 0.01% Ophthalmic Solution through year 4
Treatment: OT-101 Ophthalmic Solution
- OT-101 plus vehicleTreatment being tested
Atropine Sulfate 0.01% Ophthalmic Solution through year 3 followed by vehicle for 1 year
Treatment: OT-101 Ophthalmic Solution and Vehicle
- VehiclePlacebo, for comparison
Vehicle (Investigational Product minus active ingredient) through year 4
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase III, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Study of the Safety and Efficacy of OT-101 (Atropine Sulfate 0.01%) in Treating the Progression of Myopia in Pediatric Subjects
- Record updated
- 8 August 2023